pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation

Leukemia and Lymphoma

Volumn 50, Issue 8, 2009, Pages 1276-1282

  Stewart, Douglas A ^a   Bahlis, Nizar ^a   Mansoor, Adnan ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

biomarker; clinical results; Lymphoma and Hodgkin disease; prognostication

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53; RITUXIMAB; STAT3 PROTEIN; VINCRISTINE; BEAM PROTOCOL; CHOP PROTOCOL; PHOSPHOTYROSINE; PODOPHYLLOTOXIN; STAT3 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; DRUG MEGADOSE; EVENT FREE SURVIVAL; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SCORING SYSTEM; TREATMENT OUTCOME; AUTOTRANSPLANTATION; BIOPSY; CHEMISTRY; DISEASE FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; STATISTICS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CARMUSTINE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MELPHALAN; MIDDLE AGED; NEOPLASM PROTEINS; PHOSPHORYLATION; PHOSPHOTYROSINE; PODOPHYLLOTOXIN; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PROCESSING, POST-TRANSLATIONAL; STAT3 TRANSCRIPTION FACTOR; TRANSPLANTATION, AUTOLOGOUS; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE;

EID: 77649305748     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903015628     Document Type: Article

References (26)

1. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282. (Pubitemid 38029949)
2. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207-4213. (Pubitemid 43801342)
3. Wilson KS, Sehn LH, Berry B, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma 2007;48:1102-1109. (Pubitemid 47009200)
4. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2 - associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-4284. (Pubitemid 36857789)
5. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861. (Pubitemid 46348180)
6. Farinha P, Sehn L, Skinnider B, et al. Strong p53 expression is an independent predictor of outcome in de novo diffuse large B cell lymphoma (DLBCL) treated with either CHOP or CHOP-R. Blood 2006;108:244a (abstract 812).
7. Natkunam Y, Farinha P, Hsi ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2008;26:447-454. (Pubitemid 351171698)
8. Greb A, Bohlius J, Trelle S, et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. Cancer Treat Rev 2007;33:338-346. (Pubitemid 46778207)
9. Stewart DA, Bahlis N, Valentine K, et al. Upfront double highdose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2006;107:4623-4627. (Pubitemid 43882606)
10. Maartense E, Kramer MH, Le Cessie S, et al. Lack of prognostic significance of BCL2 and p53 protein overexpression in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma: results from a population-based non-Hodgkin's lymphoma registry. Leuk Lymphoma 2004;45:101-107. (Pubitemid 38181400)
11. Chilosi M, Doglioni C, Magalini A, et al. p21/WAF1 cyclinkinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood 1996;88:4012-4020. (Pubitemid 26383126)
12. Visco C, Canal F, Parolini C, et al. The impact of P53 and P21 (waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma. Haematologica 2006;91:687-690. (Pubitemid 43799471)
13. Khoury JD, Medeiros LJ, Rassidakis GZ, et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK7 anaplastic large cell lymphoma. Clin Cancer Res 2003;9:3692-3699. (Pubitemid 37169237)
14. Zamo A, Chiarle R, Piva R, et al. Anaplastic lymphoma kinase (ALK) activates stat3 and protects hematopoietic cells from cell death. Oncogene 2002;21:1038-1047. (Pubitemid 34174516)
15. Cho-Vega JH, Rassidakis GZ, Amin HM, et al. Suppressor of cytokine signalling 3 expression in analplastic large cell lymphoma. Leukemia 2004;18:1872-1878. (Pubitemid 39530018)
16. Yared MA, Khoury JD, Medeiros LJ, et al. Activation status of the JAK/STAT3 pathway in mantle cell lymphoma. Arch Pathol Lab Med 2005;129:990-996. (Pubitemid 41060635)
17. Lai R, Rassidakis GZ, Medeiros LJ, et al. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Am J Pathol 2004;164:2.
18. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006;24:995-1007. (Pubitemid 46638855)
19. Farinha P, Sehn L, Skinnider B, et al. Addition of rituximab (R) to CHOP improves survival in the non-GCB subtype of diffuse large B cell lymphoma (DLBCL). Blood 2006;108:245a (abstract 816).
20. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
21. Lam LT, Wright G, Davis RE, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{κ}B pathways in subtypes of diffuse large B cell lymphoma. Blood 2008;111:3701-3713.
22. Ding BB, Yu JJ, Yu RY, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008;111:1515-1523. (Pubitemid 351213441)
23. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001;61:5137-5144. (Pubitemid 32681546)
24. Tarella C, Zanni M, Di Nicola M, et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007;21:1802-1811. (Pubitemid 47086769)
25. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947. (Pubitemid 34651353)
26. Moskowitz CH, Zelenetz AD, Kewalramani T, et al. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 2005;106:3383-3385. (Pubitemid 41609171)